Oligonucleotide therapy mitigates disease in spinocerebellar ataxia type 3 miceHayley S. McLoughlin, Henry L. Paulson|Annals of Neurology|2018Cited by 156
ASOs are an effective treatment for disease-associated oligodendrocyte signatures in premanifest and symptomatic SCA3 miceKristen H. Schuster, Hayley S. McLoughlin|Molecular Therapy|2024Cited by 19
Disease-associated oligodendrocyte signatures are spatiotemporally dysregulated in spinocerebellar ataxia type 3Kristen H. Schuster, Hayley S. McLoughlin|Frontiers in Neuroscience|2023Cited by 16
ASOs are an effective treatment for disease-associated oligodendrocyte signatures in premanifest and symptomatic SCA3 miceKristen H. Schuster, Hayley S. McLoughlin|bioRxiv (Cold Spring Harbor Laboratory)|2022Cited by 2
Early transcriptomic perturbations highlight the spinal cord as a key pathogenic region in spinocerebellar ataxia type 3Jacen Emerson, Hayley S. McLoughlin|Frontiers in Cellular Neuroscience|2026Cited by 0